Biotech companies are making monumental strides in cancer treatment, leveraging cutting-edge technologies to redefine the ...
BofA reinstated coverage of Gilead (GILD) with a Buy rating and $109 price target The investment case is “simple,” namely that Gilead is a ...
In a report released today, Geoff Meacham from Citi maintained a Buy rating on Gilead Sciences (GILD – Research Report). The company’s shares ...
Crypto Ecosystem Is Shifting from Users to Owners, says Consensys ...